- Conditions
- Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
- Interventions
- Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- HonorHealth Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 2,699
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- Enzalutamide, EPI-7386 with Enzalutamide
- Drug
- Lead sponsor
- ESSA Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Port Saint Lucie, Florida • Tampa, Florida + 8 more
- Conditions
- Fructan Intolerance
- Interventions
- Sacrosidase Oral Solution, Placebo
- Drug
- Lead sponsor
- QOL Medical, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Low Grade Glioma
- Interventions
- Vinblastine, Bevacizumab
- Drug
- Lead sponsor
- The Hospital for Sick Children
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2026
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 2 more
- Conditions
- Systemic Lupus Erythematosus, SLE, Lupus
- Interventions
- JBT-101, Placebo
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 109 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 11 more
- Conditions
- Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
- Interventions
- anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 6
- States / cities
- Cary, North Carolina • Chapel Hill, North Carolina • Garner, North Carolina + 2 more
- Conditions
- Acute HIV Infection, HIV Infections
- Interventions
- efavirenz, emtricitabine, and tenofovir
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 92 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Durham, North Carolina
- Conditions
- Melanoma, Malignant Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Interventions
- therapeutic conventional surgery, laboratory biomarker analysis, Axitinib, pharmacological study
- Procedure · Other · Drug
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Vincristine Sulfate Liposomes Injection, Dexamethasone
- Drug
- Lead sponsor
- Acrotech Biopharma Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 3
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Houston, Texas
- Conditions
- Tobacco Dependence
- Interventions
- Innovative System, Standard Treatment Control (STC)
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Bone Pain in Stage I - III Breast Cancer
- Interventions
- Naproxen, Loratadine, Pegfilgrastim, Chemotherapy
- Drug · Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 100 Years · Female only
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 83
- States / cities
- Muscle Shoals, Alabama • Anaheim, California • Fullerton, California + 78 more
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
- Interventions
- INCB001158, Pembrolizumab
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 13
- States / cities
- Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- S227928, Venetoclax
- Drug
- Lead sponsor
- Servier Bio-Innovation LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Duarte, California • Fairway, Kansas • Grand Rapids, Michigan + 2 more
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Oligoprogressive Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Computed Tomography, Copper Cu 64-DOTA-pembrolizumab, Low Dose Radiation Therapy, Pembrolizumab, Positron Emission Tomography, Stereotactic Body Radiation Therapy
- Procedure · Radiation · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- Placebo (matching), Beta-blockers
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Pleasanton, California
- Conditions
- Diffuse Large B-cell Lymphoma
- Interventions
- SAR3419
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Augusta, Georgia • Boise, Idaho
- Conditions
- Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
- Interventions
- EIS-12656, Olaparib, Trastuzumab deruxtecan
- Drug
- Lead sponsor
- Eisbach Bio GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 144 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Gastrointestinal Stromal Tumors, Sdh, GIST, Cancer
- Interventions
- Temozolomide
- Drug
- Lead sponsor
- Adam Burgoyne, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 4
- States / cities
- La Jolla, California • Miami, Florida • Portland, Oregon + 1 more
- Conditions
- Metastatic Breast Cancer
- Interventions
- IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Atezolizumab, Cobimetinib
- Biological · Drug
- Lead sponsor
- Niharika Mettu
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Renal Cell Carcinoma
- Interventions
- Optison
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Interventions
- Biospecimen Collection, Drug Withdrawn, Quality-of-Life Assessment, Questionnaire Administration, Tyrosine Kinase Inhibitor
- Procedure · Other · Drug
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 25 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 157
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 123 more
- Conditions
- Locally Advanced Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Unresectable Primary Central Chondrosarcoma
- Interventions
- Belinostat, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Decitabine and Cedazuridine, Guadecitabine, Magnetic Resonance Imaging
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 32 more
- Conditions
- Peritoneal Carcinomatosis
- Interventions
- Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
- Drug · Device
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Tampa, Florida